The objective of our study is to evaluate the pCR rate following neoadjuvant therapy in a real-world cohort of patients with HER2-positive early breast cancer and to identify clinicopathological factors associated with a higher probability of achieving pCR and longer survival. This evidence concerns the gene ERBB2 and breast carcinoma.